Search results for "Injections"

showing 10 items of 518 documents

The pancreatic beta-cell response to intravenous administration of glucose in elderly subjects.

1970

A study was made of the serum insulin level after the intravenous administration of glucose (0.33 gm/ kg) in two groups of normal subjects—18 in the 60–85 age bracket, and 16 in the 23–45 age bracket. All had a normal coefficient of glucose utilization and a normal blood glucose curve after intravenous administration of glucose. Serum insulin was assayed by the radio-immunological method, with use of an ion exchange resin. Blood samples were drawn at 2, 5, 10, 30, 45 and 60 minutes after the end of the glucose infusion. In the elderly subjects the maximal value was reached only after 5 minutes and the mean value was 39± 9 µU/ml (range, 27–50), whereas in the younger subjects the serum insul…

AdultBlood GlucoseGlucose utilizationmedicine.medical_specialtymedicine.medical_treatmentRadioimmunoassayStimulationGlucose infusionInternal medicineMedicineHumansInsulinPancreasAgedbusiness.industryInsulinMean valueAge FactorsGlucose Tolerance TestMiddle AgedPeripheralEndocrinologyGlucoseInjections IntravenousGeriatrics and GerontologyBeta cellbusinessNormal blood glucoseJournal of the American Geriatrics Society
researchProduct

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

Evaluation of CGMS® During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes

2006

CGMS (Medtronic Minimed, Duesseldorf, Germany) allows continuous glucose monitoring. Recent studies with invasive monitoring techniques revealed discrepancies in blood glucose measurements obtained from different anatomical sites compared with those from the fingertip. The aim of this study was to investigate the CGMS and a device for alternative site testing (AST) during dynamic blood glucose changes and to compare these results with fingertip measurements.Twelve patients with type 1 diabetes (seven women, five men; age, 33.3 +/- 8.7 years) received a 75-g oral glucose load. Insulin was applied intravenously (rapid glucose decline) or subcutaneously (moderate glucose decline) in a dosage b…

AdultBlood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyForearmDiabetes mellitusmedicineHumansHypoglycemic AgentsInsulinIn patientBlood Glucose MeasurementType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringSite testingInsulinGlucose MeasurementMiddle Agedmedicine.diseaseSurgeryMedical Laboratory TechnologyDiabetes Mellitus Type 1medicine.anatomical_structureAnesthesiaInjections IntravenousFemalebusinessDiabetes Technology & Therapeutics
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Curasan PRP kit vs. PCCS PRP system

2002

An important reason to improve methods of isolating platelet-rich plasma (PRP) is the potential use of autologous thrombocyte growth factors. In addition to discontinuous cell separation, two methods for extracting PRP that can be performed directly by the surgeon are now available. This study compared the suitability of these two methods for the preparation of PRP. Whole blood was drawn from 47 healthy donors (18 men, 29 women) aged 20-59 years (mean 29.9, SD 7.7). For each donor, PRP was separated by the PCCS method (PCCS Kit, 3i Implant Innovations, Palm Beach Gardens, FL, USA) and by the Curasan method (analogous to the PRP kit, Curasan, Kleinostheim, Germany). Thrombocyte counts differ…

AdultBlood PlateletsMaleMatched Pair AnalysisMatched-Pair AnalysisStatistics as TopicEfficiencyBuffy coatBiologyStatistics NonparametricInjectionsAndrologySex FactorsSex factorsThrombocyte countCatheterization PeripheralCell separationHumansPlateletGrowth SubstancesWhole bloodPlatelet CountSyringesPlateletpheresisAge FactorsAnticoagulantsEquipment DesignMiddle AgedNeedlesPlatelet-rich plasmaImmunologyFemaleOral SurgeryClinical Oral Implants Research
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.

2014

SummaryThis case report concerns a pregnant multipara (age: 27 years) in the 16th gestational week. She developed a sudden onset of paraesthesia in her left lower arm although injecting dalteparin 5000 IU once daily subcutaneously (s. c.) due to a heterozygous factor V Leiden mutation and a prior miscarriage in the first pregnancy and preeclampsia in her third pregnancy. After the miscarriage she delivered two healthy children under prophylactic anticoagulation with low molecular weight heparin (LMWH). Now via magnetic resonance imaging (MRI) she was diagnosed as having multiple cerebral ischaemic lesions. Further workup revealed the presence of a patent foramen ovale (PFO) II° but no venou…

AdultDalteparinmedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPregnancy Complications CardiovascularLow molecular weight heparinForamen Ovale PatentThrombophiliaPreeclampsiaMiscarriageBrain IschemiaPregnancyRecurrencemedicineHumansThrombophiliaPregnancybusiness.industryPregnancy Complications HematologicAnticoagulantsHematologymedicine.diseaseSurgeryVenous thrombosisTreatment OutcomeAnesthesiaPatent foramen ovaleGestationFemalebusinessHamostaseologie
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct

Kardiale MRT : Änderungen der normalisierten myokardialen Gadolinium-Anreicherung über die Zeit nach Kontrastmittelinjektion in Patienten mit akuter …

2011

PURPOSE An increased normalized gadolinium accumulation (NGA) in the myocardium during early washout has been used for the diagnosis of acute myocarditis (AM). Due to the fact that the pharmacokinetics of contrast agents are complex, time-related changes in NGA after contrast injection are likely. Because knowledge about time-related changes of NGA may improve the diagnostic accuracy of MR, our study aimed to estimate the time course of NGA after contrast injection in patients as well as in healthy volunteers. MATERIALS AND METHODS An ECG-triggered inversion recovery SSFP sequence with incrementally increasing inversion times was repetitively acquired over the 15 minutes after injection of …

AdultGadolinium DTPAMalemedicine.medical_specialtymedia_common.quotation_subjectGadoliniumCardiac-Gated Imaging TechniquesMedizinchemistry.chemical_elementContrast MediaSensitivity and SpecificityPharmacokineticsReference ValuesInternal medicineHealthy volunteersmedicineImage Processing Computer-AssistedContrast (vision)HumansRadiology Nuclear Medicine and imagingIn patientMuscle Skeletalmedia_commonbusiness.industryMyocardiumWashoutSteady-state free precession imagingMiddle AgedImage EnhancementMagnetic Resonance ImagingMyocardial ContractionMyocarditischemistryContrast injectionAcute DiseaseInjections IntravenousCardiologyFemalebusiness
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct